Simply Wall St.6d agobearish
Boston Scientific (BSX) Is Up 7.1% After Q2 Beat, Recall And Major Restructuring Plan - Has The Bull Case Changed?Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...
